INT206764

Latest revision as of 00:29, 21 September 2012

Context	Info
Confidence	0.05
First Reported	2007
Last Reported	2010
Negated	0
Speculated	0
Reported most in	Body
Documents	8
Total Number	9
Disease Relevance	13.45
Pain Relevance	2.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (AQP4, Nqo1)	cytosol (Nqo1)	transport (AQP4)
oxidoreductase activity (Nqo1)	plasma membrane (AQP4)	transmembrane transport (AQP4)

AQP4 (Homo sapiens)

Nqo1 (Mus musculus)

Pain Link	Frequency	Relevance
Multiple sclerosis	100	100.00
Demyelination	16	99.46
medulla	2	95.96
Spinal cord	52	92.32
Central nervous system	36	90.92
addiction	9	84.08
Neuritis	97	81.76
imagery	10	74.52
Inflammation	59	60.48
intrathecal	36	53.36

Disease Link	Frequency	Relevance
Neuromyelitis Optica	481	100.00
Demyelinating Disease	220	100.00
Necrosis	6	99.70
Autonomic Nervous System Disease	2	97.36
Disease	261	96.04
Respiratory Failure	5	94.08
Autoimmune Disease	19	92.68
Channelopathies	2	91.72
Central Nervous System Disease	22	90.92
Syndrome	24	87.52

[edit] Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Lennon and colleagues discovered a biomarker for NMO; NMO-IgG is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which binds to aquaporin-4 (AQP4) [11], the most abundant water channel in the CNS [12-14].

AQP4 Binding (binds) of NMO-IgG associated with neuromyelitis optica and multiple sclerosis

1)	Confidence	0.05	Published	2010	Journal	J Neuroinflammation	Section	Body	Doc Link	PMC2941752	Disease Relevance	2.72	Pain Relevance	0.75

Lennon and colleagues discovered a biomarker for NMO; NMO-IgG is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which binds to aquaporin-4 (AQP4) [11], the most abundant water channel in the CNS [12-14].

aquaporin-4 Binding (binds) of NMO-IgG associated with neuromyelitis optica and multiple sclerosis

2)	Confidence	0.05	Published	2010	Journal	J Neuroinflammation	Section	Body	Doc Link	PMC2941752	Disease Relevance	2.72	Pain Relevance	0.74

Thus we hypothesized that AQP4 antibodies in fact characterize NMO patients.

AQP4 Binding (characterize) of NMO associated with neuromyelitis optica

3)	Confidence	0.03	Published	2007	Journal	PLoS Medicine	Section	Abstract	Doc Link	PMC1852124	Disease Relevance	1.17	Pain Relevance	0.17

It is therefore still unclear whether antibodies to AQP4 are specific for NMO and whether testing for these antibodies may be useful for its diagnosis and its distinction from diseases with similar clinical and neuroradiological patterns, such as MS and other autoimmune diseases with involvement of the CNS.

AQP4 Binding (specific) of NMO associated with neuromyelitis optica, multiple sclerosis, autoimmune disease, central nervous system and disease

4)	Confidence	0.03	Published	2007	Journal	PLoS Medicine	Section	Body	Doc Link	PMC1852124	Disease Relevance	1.74	Pain Relevance	0.29

The limited access of circulating IgG to the extracapillary space in the CNS would only permit interaction of NMO-IgG with AQP4 at the glia limitans of BBB: in consequence of these findings, many authors suggest the perivascular space as the primary target site of the pathogenic process.

AQP4 Binding (interaction) of NMO associated with neuromyelitis optica

5)	Confidence	0.02	Published	2010	Journal	Current Neuropharmacology	Section	Body	Doc Link	PMC2923365	Disease Relevance	1.09	Pain Relevance	0.17

Moreover, two pathologic patterns in NMO, both of which were associated with loss of AQP4 immunoreactivity were described [39].

AQP4 Binding (associated) of NMO associated with neuromyelitis optica

6)	Confidence	0.02	Published	2010	Journal	Current Neuropharmacology	Section	Body	Doc Link	PMC2923365	Disease Relevance	1.33	Pain Relevance	0.35

In summary, the intriguing report by Roemer and colleagues [80], describing loss of AQP4 in the absence of demyelination or necrosis suggests that binding of antibody to AQP4 may be the initial pathogenic event in NMO lesions.

AQP4 Binding (binding) of NMO associated with neuromyelitis optica, necrosis and demyelination

7)	Confidence	0.02	Published	2010	Journal	Current Neuropharmacology	Section	Body	Doc Link	PMC2923365	Disease Relevance	1.27	Pain Relevance	0.31

In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG).

aquaporin-4 Binding (associated) of NMO associated with neuromyelitis optica

8)	Confidence	0.01	Published	2010	Journal	J Neuroinflammation	Section	Abstract	Doc Link	PMC2945323	Disease Relevance	0.70	Pain Relevance	0.03

In 70-80% of cases, neuromyelitis optica (NMO) is associated with highly specific serum auto-antibodies to aquaporin-4 (termed AQP4-Ab or NMO-IgG).

AQP4 Binding (associated) of NMO associated with neuromyelitis optica

9)	Confidence	0.01	Published	2010	Journal	J Neuroinflammation	Section	Abstract	Doc Link	PMC2945323	Disease Relevance	0.70	Pain Relevance	0.03

[edit] General Comments

This test has worked.

INT206764

Latest revision as of 00:29, 21 September 2012

[edit] Sentences Mentioned In

[edit] General Comments

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Toolbox

@@ Line 7: / Line 7: @@
 |-
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.1904229200
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.05
 |-
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| First Reported
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2007
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2007|2007]]
 |-
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Last Reported
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 |-
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Negated
@@ Line 22: / Line 22: @@
 |-
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Reported most in
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| NULL
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| Body
 |-
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Documents
@@ Line 29: / Line 29: @@
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Total Number
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 9
+|-
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 13.45
+|-
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"| Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;" align="center"| 2.84
 |-
 |}
@@ Line 42: / Line 48: @@
 fontcolor=white,
 label="Binding",
-URL=Binding
+URL="http://wikipaints.org/vhosts/wikipaints/mediawiki-1.19.1/index.php?title=E:Binding"
 ];
 node2
@@ Line 50: / Line 56: @@
 fontcolor=white,
 label="AQP4",
-URL="AQP4"
+URL="http://wikipaints.org/vhosts/wikipaints/mediawiki-1.19.1/index.php?title=G:361"
 ];
 node3
@@ Line 58: / Line 64: @@
 fontcolor=white,
 label="Nqo1",
-URL="Nqo1"
+URL="http://wikipaints.org/vhosts/wikipaints/mediawiki-1.19.1/index.php?title=G:18104"
 ];
 subgraph cluster_0 {
@@ Line 72: / Line 78: @@
 {| cellspacing=5 cellpadding=2
 |-
-| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[cytoplasm]] ([[AQP4]], [[Nqo1]])
+| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:cytoplasm|cytoplasm]] ([[G:361|AQP4]], [[G:18104|Nqo1]])
-| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[cytosol]] ([[Nqo1]])
+| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:cytosol|cytosol]] ([[G:18104|Nqo1]])
-| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[transport]] ([[AQP4]])
+| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:transport|transport]] ([[G:361|AQP4]])
 |-
-| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[oxidoreductase activity]] ([[Nqo1]])
+| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:oxidoreductase activity|oxidoreductase activity]] ([[G:18104|Nqo1]])
-| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[plasma membrane]] ([[AQP4]])
+| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:plasma membrane|plasma membrane]] ([[G:361|AQP4]])
-| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[transmembrane transport]] ([[AQP4]])
+| style="color: black; background:#F7F7CD; border: 1px solid lightgray; white-space:wrap;"| [[GOS:transmembrane transport|transmembrane transport]] ([[G:361|AQP4]])
 |-
 |}
@@ Line 92: / Line 98: @@
 |-
 |}
 |-
-|colspan="3"|
+|}
-{| cellspacing=1 cellpadding=1
+{| cellspacing=2 cellpadding=2
-|
+| style="vertical-align: top"|
 {| cellspacing=1 cellpadding=5 align=center
 |-
-| style="color: black; background:#AAFCFB; white-space:wrap;"| '''Pain Relations:'''
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Pain Link
-(frequency)
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Frequency
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Demyelination]] (16)
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Relevance
-{{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Heat
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Brainstem]] (2)
-{{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Corticosteroids]] (4)
-{{#icon: cold.png|Quite Low}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Functional magnetic resonance imaging]] (10)
-{{#icon: cold.png|Low}} {{#icon: cold.png|Low}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Gray cellular mantle]] (6)
-{{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Spinal cord]] (52)
-{{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Central nervous system]] (36)
-{{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[midbrain]] (6)
-{{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}} {{#icon: cold.png|Very Low}}
 |-
-| style="color: black; background:#AAFCFB; white-space:wrap;"| '''Disease Relations:'''
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Multiple sclerosis|Multiple sclerosis]]
-(frequency)
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Autonomic Nervous System Disease]] (2)
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100.00
-{{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Respiratory Failure]] (5)
-{{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Channelopathies]] (2)
-{{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Syndrome]] (24)
-{{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Hyalinosis]] (3)
-{{#icon: chilli.png|Quite High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Necrosis]] (6)
-{{#icon: chilli.png|Quite High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Hyperplasia]] (3)
-{{#icon: chilli.png|Quite High}}
-| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[Congenital Anomalies]] (8)
-{{#icon: chilli.png|Quite High}}
-|}
-{| cellpadding=3 cellspacing=0
 |-
-! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Protein
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Demyelination|Demyelination]]
-! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;" align="center"| Mutation
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 16
-! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;" align="center"| Frequency
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 99.46
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:medulla|medulla]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 95.96
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Spinal cord|Spinal cord]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 52
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 92.32
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Central nervous system|Central nervous system]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 36
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90.92
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:addiction|addiction]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 9
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 84.08
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Neuritis|Neuritis]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 97
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 81.76
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:imagery|imagery]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 10
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 74.52
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:Inflammation|Inflammation]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 59
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 60.48
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[P:intrathecal|intrathecal]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 36
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 53.36
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Quite High}}
 |-
 |}
+|
+| style="vertical-align: top"|
+{| cellspacing=1 cellpadding=5 align=center
 |-
-|}
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Disease Link
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Frequency
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Relevance
+! style="color: black; background:#AAFCFB; white-space:wrap;"| Heat
 |-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Neuromyelitis Optica|Neuromyelitis Optica]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 481
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100.00
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Demyelinating Disease|Demyelinating Disease]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 220
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 100.00
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Necrosis|Necrosis]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 6
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 99.70
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Autonomic Nervous System Disease|Autonomic Nervous System Disease]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 97.36
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Disease|Disease]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 261
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 96.04
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}} {{#icon: chilli.png|Very High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Respiratory Failure|Respiratory Failure]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 5
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 94.08
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Autoimmune Disease|Autoimmune Disease]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 19
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 92.68
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Channelopathies|Channelopathies]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 2
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 91.72
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Central Nervous System Disease|Central Nervous System Disease]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 22
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 90.92
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
+|-
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| [[D:Syndrome|Syndrome]]
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 24
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| 87.52
+| style="background:#E0FFFF; border: 1px solid white; white-space:wrap;"| {{#icon: chilli.png|High}} {{#icon: chilli.png|High}}
+|-
+|}
 |}
@@ Line 155: / Line 230: @@
 | style="color: black; background:white; white-space:wrap;"| Key:
 | style="color: black; background:#FFFF00; border: 1px solid lightgray; white-space:wrap;"| Protein
+| style="color: black; background:#ADFF2F; border: 1px solid lightgray; white-space:wrap;"| Mutation
 | style="color: black; background:#B0E0E6; border: 1px solid lightgray; white-space:wrap;"| Event
 | style="color: black; background:#FFDEAD; border: 1px solid lightgray; white-space:wrap;"| Anatomy
@@ Line 160: / Line 236: @@
 | style="color: black; background:#D3D3D3; border: 1px solid lightgray; white-space:wrap;"| Speculation
 | style="color: black; background:#FFA07A; border: 1px solid lightgray; white-space:wrap;"| Pain term
+| style="color: black; background:#FFA07A; border: 1px solid lightgray; white-space:wrap;"| Disease term
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| Lennon and colleagues discovered a biomarker for NMO; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which <span style="background-color:#B0E0E6">binds</span> to aquaporin-4 (<span style="background-color:#FFFF00">AQP4</span>) [11], the most abundant water channel in the CNS [12-14].
+| Lennon and colleagues discovered a biomarker for <span style="background-color:#FFA07A">NMO</span>; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of <span style="background-color:#FFA07A">NMO</span> but less than 5% of <span style="background-color:#FFA07A">CMS</span> patients [10], which <span style="background-color:#B0E0E6">binds</span> to aquaporin-4 (<span style="background-color:#FFFF00">AQP4</span>) [11], the most abundant water channel in the CNS [12-14].
 |-
 |
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">binds</span>) of <span style="color:#800000">'''NMO-IgG'''</span>
+|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">binds</span>) of [[G:18104|<span style="color:#800000">'''NMO-IgG'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span> and <span style="color:#FF0000">'''multiple sclerosis'''</span>
 |-
 |}
@@ Line 177: / Line 254: @@
 ! style="color: black; background:white; white-space:nowrap;"| 1)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.0466765778031529
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.05
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Body
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2941752 PMC2941752]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2.72
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.75
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| Lennon and colleagues discovered a biomarker for NMO; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of NMO but less than 5% of CMS patients [10], which <span style="background-color:#B0E0E6">binds</span> to <span style="background-color:#FFFF00">aquaporin-4</span> (AQP4) [11], the most abundant water channel in the CNS [12-14].
+| Lennon and colleagues discovered a biomarker for <span style="background-color:#FFA07A">NMO</span>; <span style="background-color:#FFFF00">NMO-IgG</span> is an autoantibody initially detected in the serum of 73% of <span style="background-color:#FFA07A">NMO</span> but less than 5% of <span style="background-color:#FFA07A">CMS</span> patients [10], which <span style="background-color:#B0E0E6">binds</span> to <span style="background-color:#FFFF00">aquaporin-4</span> (AQP4) [11], the most abundant water channel in the CNS [12-14].
 |-
 |
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''aquaporin-4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">binds</span>) of <span style="color:#800000">'''NMO-IgG'''</span>
+|  [[G:361|<span style="color:#800000">'''aquaporin-4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">binds</span>) of [[G:18104|<span style="color:#800000">'''NMO-IgG'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span> and <span style="color:#FF0000">'''multiple sclerosis'''</span>
 |-
 |}
@@ Line 204: / Line 285: @@
 ! style="color: black; background:white; white-space:nowrap;"| 2)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.0466765778031529
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.05
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Body
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2941752 PMC2941752]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2.72
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.74
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| Thus we hypothesized that <span style="background-color:#FFFF00">AQP4</span> antibodies in fact <span style="background-color:#B0E0E6">characterize</span> <span style="background-color:#FFFF00">NMO</span> patients.
+| Thus we hypothesized that <span style="background-color:#FFFF00">AQP4</span> antibodies in fact <span style="background-color:#B0E0E6">characterize</span> <span style="background-color:#FFA07A">NMO</span> patients.
@@ Line 224: / Line 309: @@
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">characterize</span>) of <span style="color:#800000">'''NMO'''</span>
+|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">characterize</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 |-
 |}
@@ Line 233: / Line 318: @@
 ! style="color: black; background:white; white-space:nowrap;"| 3)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.0285731317677099
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2007
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2007|2007]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:PLoS Medicine|PLoS Medicine]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Abstract
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC1852124 PMC1852124]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.17
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.17
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| It is therefore still unclear whether antibodies to <span style="background-color:#FFFF00">AQP4</span> are <span style="background-color:#B0E0E6">specific</span> for <span style="background-color:#FFFF00">NMO</span> and whether testing for these antibodies may be useful for its diagnosis and its distinction from diseases with similar clinical and neuroradiological patterns, such as MS and other autoimmune diseases with involvement of the CNS.
+| It is therefore still unclear whether antibodies to <span style="background-color:#FFFF00">AQP4</span> are <span style="background-color:#B0E0E6">specific</span> for <span style="background-color:#FFA07A">NMO</span> and whether testing for these antibodies may be useful for its diagnosis and its distinction from <span style="background-color:#FFA07A">diseases</span> with similar clinical and neuroradiological patterns, such as <span style="background-color:#FFA07A">MS</span> and other <span style="background-color:#FFA07A">autoimmune diseases</span> with involvement of the <span style="background-color:#FFA07A">CNS</span>.
 |-
 |
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">specific</span>) of <span style="color:#800000">'''NMO'''</span>
+|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">specific</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>, <span style="color:#FF0000">'''multiple sclerosis'''</span>, <span style="color:#FF0000">'''autoimmune disease'''</span>, <span style="color:#FF0000">'''central nervous system'''</span> and <span style="color:#FF0000">'''disease'''</span>
 |-
 |}
@@ Line 260: / Line 349: @@
 ! style="color: black; background:white; white-space:nowrap;"| 4)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.0274655216036807
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2007
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2007|2007]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:PLoS Medicine|PLoS Medicine]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Body
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC1852124 PMC1852124]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.74
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.29
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| The limited access of circulating IgG to the extracapillary space in the CNS would only permit <span style="background-color:#B0E0E6">interaction</span> of <span style="background-color:#FFFF00">NMO</span>-IgG with <span style="background-color:#FFFF00">AQP4</span> at the glia limitans of BBB: in consequence of these findings, many authors suggest the perivascular space as the primary target site of the pathogenic process.
+| The limited access of circulating IgG to the extracapillary space in the CNS would only permit <span style="background-color:#B0E0E6">interaction</span> of <span style="background-color:#FFA07A">NMO</span>-IgG with <span style="background-color:#FFFF00">AQP4</span> at the glia limitans of BBB: in consequence of these findings, many authors suggest the perivascular space as the primary target site of the pathogenic process.
 |-
 |
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">interaction</span>) of <span style="color:#800000">'''NMO'''</span>
+|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">interaction</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 |-
 |}
@@ Line 287: / Line 380: @@
 ! style="color: black; background:white; white-space:nowrap;"| 5)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.0229482138959204
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Body
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.09
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.17
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| Moreover, two pathologic patterns in <span style="background-color:#FFFF00">NMO</span>, both of which were <span style="background-color:#B0E0E6">associated</span> with loss of <span style="background-color:#FFFF00">AQP4</span> immunoreactivity were described [39].
+| Moreover, two pathologic patterns in <span style="background-color:#FFA07A">NMO</span>, both of which were <span style="background-color:#B0E0E6">associated</span> with loss of <span style="background-color:#FFFF00">AQP4</span> immunoreactivity were described [39].
 |-
 |
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">associated</span>) of <span style="color:#800000">'''NMO'''</span>
+|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">associated</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 |-
 |}
@@ Line 314: / Line 411: @@
 ! style="color: black; background:white; white-space:nowrap;"| 6)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.0177522037091431
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Body
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.33
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.35
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| In summary, the intriguing report by Roemer and colleagues [80], describing loss of AQP4 in the absence of demyelination or necrosis suggests that <span style="background-color:#B0E0E6">binding</span> of antibody to <span style="background-color:#FFFF00">AQP4</span> may be the initial pathogenic event in <span style="background-color:#FFFF00">NMO</span> lesions.
+| In summary, the intriguing report by Roemer and colleagues [80], describing loss of AQP4 in the absence of <span style="background-color:#FFA07A">demyelination</span> or <span style="background-color:#FFA07A">necrosis</span> suggests that <span style="background-color:#B0E0E6">binding</span> of antibody to <span style="background-color:#FFFF00">AQP4</span> may be the initial pathogenic event in <span style="background-color:#FFA07A">NMO</span> lesions.
 |-
@@ Line 333: / Line 434: @@
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">binding</span>) of <span style="color:#800000">'''NMO'''</span>
+|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">binding</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>, <span style="color:#FF0000">'''necrosis'''</span> and <span style="color:#FF0000">'''demyelination'''</span>
 |-
 |}
@@ Line 342: / Line 443: @@
 ! style="color: black; background:white; white-space:nowrap;"| 7)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.0177522037091431
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.02
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:Current Neuropharmacology|Current Neuropharmacology]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Body
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2923365 PMC2923365]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 1.27
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.31
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| In 70-80% of cases, neuromyelitis optica (<span style="background-color:#FFFF00">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to <span style="background-color:#FFFF00">aquaporin-4</span> (termed AQP4-Ab or NMO-IgG).
+| In 70-80% of cases, <span style="background-color:#FFA07A">neuromyelitis optica</span> (<span style="background-color:#FFA07A">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to <span style="background-color:#FFFF00">aquaporin-4</span> (termed AQP4-Ab or <span style="background-color:#FFA07A">NMO</span>-IgG).
 |-
 |
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''aquaporin-4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">associated</span>) of <span style="color:#800000">'''NMO'''</span>
+|  [[G:361|<span style="color:#800000">'''aquaporin-4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">associated</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 |-
 |}
@@ Line 369: / Line 474: @@
 ! style="color: black; background:white; white-space:nowrap;"| 8)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.00502201274017981
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.01
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Abstract
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2945323 PMC2945323]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.70
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 |}
 |-
 |}
 {| style="color: black; background-color: white;" cellpadding=6 cellspacing=6 class="wikitable"
-| In 70-80% of cases, neuromyelitis optica (<span style="background-color:#FFFF00">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to aquaporin-4 (termed <span style="background-color:#FFFF00">AQP4</span>-Ab or NMO-IgG).
+| In 70-80% of cases, <span style="background-color:#FFA07A">neuromyelitis optica</span> (<span style="background-color:#FFA07A">NMO</span>) is <span style="background-color:#B0E0E6">associated</span> with highly specific serum auto-antibodies to aquaporin-4 (termed <span style="background-color:#FFFF00">AQP4</span>-Ab or <span style="background-color:#FFA07A">NMO</span>-IgG).
 |-
 |
 {| cellpadding=4 cellspacing=2
 |-
-| <span style="color:#800000">'''AQP4'''</span> <span style="color:#000080">'''Binding'''</span> (<span style="color:#000080">associated</span>) of <span style="color:#800000">'''NMO'''</span>
+|  [[G:361|<span style="color:#800000">'''AQP4'''</span>]] [[E:Binding|<span style="color:#000080">'''Binding'''</span>]] (<span style="color:#000080">associated</span>) of [[G:18104|<span style="color:#800000">'''NMO'''</span>]] associated with <span style="color:#FF0000">'''neuromyelitis optica'''</span>
 |-
 |}
@@ Line 396: / Line 505: @@
 ! style="color: black; background:white; white-space:nowrap;"| 9)
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"| Confidence
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.00502201274017981
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.01
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Published
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 2010
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[Y:2010|2010]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Journal
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [[J:J Neuroinflammation|J Neuroinflammation]]
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Section
-| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| N/A
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| Abstract
 ! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Doc Link
 | style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| [http://www.ncbi.nlm.nih.gov/pubmed?term=PMC2945323 PMC2945323]
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Disease Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.70
+! style="color: black; background:#AAFCFB; border: 1px solid lightgray; white-space:nowrap;"|    Pain Relevance
+| style="color: black; background:#F1FEFE; border: 1px solid lightgray; white-space:nowrap;"  align="center"| 0.03
 |}
 |-